Factor VIII chimeric proteins and uses thereof
The present invention provides a chimeric protein comprising a first polypeptide which comprises a FVIII protein and a first Ig constant region or a portion thereof and a second polypeptide which comprises a VWF protein comprising the D′ domain and D3 domain of VWF, a XTEN sequence having less than 288 amino acids in length, and a second Ig constant region or a portion thereof, wherein the first polypeptide and the second polypeptide are associated with each other. The invention also includes nucleotides, vectors, host cells, methods of using the chimeric proteins.
1 . A method of treating a disorder caused by a deficiency in Factor VIII comprising administering to a subject in need thereof a therapeutically effective amount of a chimeric protein comprising:
(i) a first polypeptide chain which comprises, from the N-terminus to the C-terminus thereof:
(a) a Factor VIII (“FVIII”) protein comprising a N-terminal portion and a C-terminal portion;
wherein the N-terminal portion of the FVIII protein comprises the A1 domain, A2 domain, and a portion of the B domain of full length mature FVIII (SEQ ID NO: 65);
such that the N-terminal portion comprises the amino acid sequence of residues 1 to 745 of SEQ ID NO: 65;
wherein the N-terminal portion is fused to a first XTEN sequence inserted immediately downstream of amino acid 745 of SEQ ID NO: 65; and
wherein the C-terminal portion comprises the A3 domain, the C1 domain, and the C2 domain, such that the C-terminal portion comprises residues 1690-2332 of SEQ ID NO: 65;
(b) a first immunoglobulin (“Ig”) constant region or a portion thereof,
wherein the first XTEN sequence comprises the amino acid sequence of SEQ ID NO: 8; and
(ii) a second polypeptide chain which comprises, from the N-terminus to the C-terminus thereof:
(a) a von Willebrand Factor (“VWF”) protein comprising a D′ domain and a D3 domain of VWF, wherein the VWF protein contains a residue other than cysteine substituted for residues corresponding to residues 1099 and 1142 of SEQ ID NO: 21;
(b) a second XTEN sequence comprising the amino acid sequence of SEQ ID NO: 58, wherein the second XTEN sequence contains less than 288 amino acid residues;
(c) a cleavable linker comprising an a2 region of FVIII which comprises the amino acid sequence of Glu720 to Arg740 corresponding to SEQ ID NO: 65, wherein the a2 region is capable of being cleaved by thrombin; and
(d) a second Ig constant region or a portion thereof,
wherein the first polypeptide chain is associated with the second polypeptide chain through the first Ig constant region or a portion thereof and the second Ig constant region or a portion thereof.
2 . The method of claim 1 , wherein the disorder is hemophilia A.
3 . The method of claim 2 , wherein wherein the first Ig constant region or portion thereof is associated with the second Ig constant region or portion thereof through two disulfide bonds.
4 . The method of claim 3 , wherein wherein the first Ig constant region or portion thereof is a first Fc region and the second Ig constant region or portion thereof is a second Fc region.
5 . The method of claim 4 , wherein the cleavable linker is 20 to 50 amino acids long.
6 . The method of claim 3 , wherein the cleavable linker is about 30 amino acids long.
7 . The method of claim 2 , wherein the chimeric protein is administered prophylactically.
8 . The method of claim 2 , wherein the chimeric protein is administered for on-demand treatment.
9 . The method of claim 2 , wherein the chimeric protein is administered prior to, during, or after surgery.
10 . The method of claim 2 , wherein the chimeric protein is administered to control an acute bleeding episode.
11 . A method of treating a disorder that comprises a deficiency in Factor VIII comprising intravenously administering to a subject in need thereof a therapeutically effective amount of a chimeric protein comprising:
(i) a first polypeptide chain which comprises, from the N-terminus to the C-terminus thereof:
(a) a Factor VIII (“FVIII”) protein comprising the amino acid sequence of residues 1 to 745 of SEQ ID NO: 65, fused to a first XTEN sequence inserted immediately downstream of residue 745 of SEQ ID NO: 65, fused to residues 1649 to 2332 of SEQ ID NO: 65, and
(b) a first Fc region;
wherein the first XTEN sequence comprises the amino acid sequence of SEQ ID NO: 8; and
(ii) a second polypeptide chain which comprises, from the N-terminus to the C-terminus thereof:
(a) a von Willebrand Factor (“VWF”) protein comprising a D′ domain and a D3 domain of VWF, wherein the VWF protein comprises the amino acid sequence of residues 764 to 1240 of SEQ ID NO: 21 with alanine substitutions at residues 1099 and 1142 of SEQ ID NO: 21,
(b) a second XTEN sequence comprising the amino acid sequence of SEQ ID NO: 58,
(c) a cleavable linker comprising the amino acid sequence of SEQ ID NO: 88, and
(d) a second Fc region;
wherein the first Fc region is associated with the second Fc region through a disulfide bond.
12 . A method of treating a disorder that comprises a deficiency in Factor VIII comprising intravenously administering to a subject in need thereof a therapeutically effective amount of a chimeric protein comprising:
(i) a first polypeptide chain which comprises, from the N-terminus to the C-terminus thereof:
(a) a Factor VIII (“FVIII”) protein comprising an amino acid sequence that is at least 99% identical to SEQ ID NO: 67 with a first XTEN sequence inserted immediately downstream of the residue corresponding to residue 745 of SEQ ID NO: 67; and
(b) a first Fc region;
wherein the first XTEN sequence comprises the amino acid sequence of SEQ ID NO: 8; and
(ii) a second polypeptide chain which comprises, from the N-terminus to the C-terminus thereof:
(a) a von Willebrand Factor (“VWF”) protein comprising a D′ domain and a D3 domain of VWF, wherein the VWF protein contains a residue other than cysteine substituted for residues 1099 and 1142 of SEQ ID NO: 21;
(b) a second XTEN sequence comprising the amino acid sequence of SEQ ID NO: 58, wherein the second XTEN sequence contains less than 288 amino acid residues;
(c) a cleavable linker comprising an a2 region of FVIII which comprises the amino acid sequence of Glu720 to Arg740 corresponding to SEQ ID NO: 65, wherein the a2 region is capable of being cleaved by thrombin; and
(d) a second Fc region, wherein the first Fc region is associated with the second Fc region through a disulfide bond.
13 . A method of treating a disorder that comprises a deficiency in Factor VIII comprising intravenously administering to a subject in need thereof a therapeutically effective amount of a chimeric protein comprising:
(i) a first polypeptide chain which comprises a Factor VIII (“FVIII”) protein fused to a first immunoglobulin (“Ig”) constant region or a portion thereof,
wherein the FVIII protein comprises the amino acid sequence of residues 1 to 745 of SEQ ID NO: 202, fused to a first XTEN sequence inserted immediately downstream of residue 745 of SEQ ID NO: 202, fused to residues 746 to 1429 of SEQ ID NO: 202; and
wherein the first XTEN sequence comprises the amino acid sequence of SEQ ID NO: 8; and
(ii) a second polypeptide chain which comprises a von Willebrand Factor (“VWF”) protein comprising a D′ domain and a D3 domain of VWF fused to a second Ig constant region or a portion thereof by a second XTEN sequence in-between,
wherein the VWF protein comprises the amino acid sequence of SEQ ID NO: 201;
wherein the second XTEN sequence comprises the amino acid sequence of SEQ ID NO: 58; and
wherein the second XTEN sequence is linked to the second Ig constant region or a portion thereof by a linker comprising the amino acid sequence of SEQ ID NO: 88;
wherein the first polypeptide chain is associated with the second polypeptide chain through the first Ig constant region or a portion thereof and the second Ig constant region or a portion thereof.
14 . The method of claim 1 , wherein the disorder is Von Willebrand Disease.
15 . The method of claim 14 , wherein the Von Willebrand Disease is Von Willebrand Disease type 3.
16 . The method of claim 2 , wherein the C-terminal portion of the FVIII protein comprises an amino acid sequence at least 95% identical to residues 1641 to 2332of SEQ ID NO: 65.
17 . The method of claim 16 , wherein the VWF protein contains an alanine substitution at residue 1099 and residue 1142 of SEQ ID NO: 21.
18 . The method of claim 17 , wherein the first Fc region and the second Fc region are the same.
19 . The method of claim 18 , wherein the first Fc region and the second Fc region are derived from human IgG1.
20 . The method of claim 19 , wherein the VWF protein consists of the D′ domain and the D3 domain.
21 . The method of claim 11 , wherein the disorder is hemophilia A.
22 . The method of claim 11 , wherein the disorder is Von Willebrand Disease.
23 . The method of claim 22 , wherein the Von Willebrand Disease is Von Willebrand Disease type 3.
24 . The method of claim 21 , wherein the first Fc region is associated with the second Fc region through two disulfide bonds.
25 . The method of claim 21 , wherein the second XTEN sequence links the VWF protein to the cleavable linker, such that the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 22.
26 . The method of claim 25 , wherein the first XTEN sequence is inserted into the FVIII protein such that the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 2.
27 . The method of claim 26 , wherein the first polypeptide chain comprises an amino acid sequence at least 99% identical to the amino acid sequence of SEQ ID NO: 173.
28 . The method of claim 27 , wherein the VWF protein consists of the D′ domain and the D3 domain.
29 . The method of claim 12 , wherein the disorder is hemophilia A.
30 . The method of claim 12 , wherein the disorder is Von Willebrand Disease.
31 . The method of claim 30 , wherein the Von Willebrand Disease is Von Willebrand Disease type 3.
32 . The method of claim 29 , wherein the VWF protein contains an alanine substitution at residue 1099 and residue 1142 of SEQ ID NO: 21.
33 . The method of claim 32 , wherein the first Fc region and the second Fc region are the same.
34 . The method of claim 33 , wherein the first Fc region and the second Fc region are derived from human IgG1.
35 . The method of claim 34 , wherein the VWF protein consists of the D′ domain and the D3 domain.
36 . The method of claim 33 , wherein the cleavable linker comprises an a2 region of FVIII comprising an amino acid sequence at least 90% identical to SEQ ID NO: 106.
37 . The method of claim 33 , wherein the cleavable linker is 20 to 50 amino acids long.
38 . The method of claim 37 , wherein the cleavable linker is about 30 amino acids long.
39 . The method of claim 13 , wherein the disorder is hemophilia A.
40 . The method of claim 13 , wherein the disorder is Von Willebrand Disease.
41 . The method of claim 40 , wherein the Von Willebrand Disease is Von Willebrand Disease type 3.
42 . The method of claim 39 , wherein the first Ig constant region or a portion thereof comprises a first Fc region and the second Ig constant region or a portion thereof comprises a second Fc region.
43 . The method of claim 39 , wherein the first Ig constant region or a portion thereof is associated with the second Ig constant region or a portion thereof by a covalent bond.
44 . The method of claim 39 , wherein the FVIII protein comprises a deletion of residues 746-1648 corresponding to native mature human FVIII protein (SEQ ID NO: 65).
45 . The method of claim 39 , wherein the first Ig constant region or a portion thereof is associated with the second Ig constant region or a portion thereof by a disulfide bond.
46 . The method of claim 39 , wherein the first polypeptide chain comprises an amino acid sequence at least 99% identical to SEQ ID NO: 173.
47 . The method of claim 39 , wherein the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 173.
48 . The method of claim 39 , wherein the second XTEN sequence is fused to the linker such that the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 22.
49 . The method of claim 39 , wherein the second XTEN sequence is linked to the second Ig constant region or a portion thereof by a linker consisting of the amino acid sequence of SEQ ID NO: 88.
50 . The method of claim 48 , wherein the first XTEN sequence is inserted into the FVIII protein such that the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 2.
51 . The method of claim 42 , wherein the first Fc region and the second Fc region are identical.
52 . The method of claim 42 , wherein the first Fc region and the second Fc region are derived from human IgG1.
53 . The method of claim 39 , wherein the first Ig constant region or a portion thereof is associated with the second Ig constant region or a portion thereof by two disulfide bonds.
54 . The method of claim 39 , wherein the VWF protein consists of the D′ domain and the D3 domain.
55 . A method of treating a disorder that comprises a deficiency in Factor VIII comprising intravenously administering to a subject in need thereof a therapeutically effective amount of a chimeric protein comprising:
(i) a first polypeptide chain which comprises, from the N-terminus to the C-terminus thereof:
(a) a Factor VIII (“FVIII”) protein comprising the amino acid sequence of residues 1 to 745 of SEQ ID NO: 65, fused to a first XTEN sequence inserted immediately downstream of residue 745 of SEQ ID NO: 65, fused to residues 1649 to 2332 of SEQ ID NO: 65, and
(b) a first Fc region;
wherein the first XTEN sequence comprises the amino acid sequence of SEQ ID NO: 8; and
(ii) a second polypeptide chain which comprises, from the N-terminus to the C-terminus thereof:
(a) a von Willebrand Factor (“VWF”) protein comprising a D′ domain and a D3 domain of VWF, wherein the VWF protein comprises the amino acid sequence of residues 764 to 1240of SEQ ID NO: 21 with alanine substitutions at residues 1099 and 1142 of SEQ ID NO: 21,
(b) a second XTEN sequence comprising the amino acid sequence of SEQ ID NO: 58, wherein the second XTEN sequence contains less than 288 amino acid residues;
(c) a cleavable linker comprising an a2 region of FVIII which comprises the amino acid sequence of Glu720 to Arg740 corresponding to SEQ ID NO: 65, wherein the a2 region is capable of being cleaved by thrombin; and
(d) a second Fc region;
wherein the first Fc region is associated with the second Fc region through a disulfide bond.
56 . The method of claim 55 , wherein the disorder is hemophilia A.
57 . The method of claim 55 , wherein the disorder is Von Willebrand Disease.
58 . The method of claim 57 , wherein the Von Willebrand Disease is Von Willebrand Disease type 3.
59 . The method of claim 56 , wherein the first Fc region and the second Fc region are the same.
60 . The method of claim 59 , wherein the first Fc region and the second Fc region are derived from human IgG1.
61 . The method of claim 60 , wherein the VWF protein consists of the D′ domain and the D3 domain.
62 . The method of claim 59 , wherein the cleavable linker comprises an a2 region of FVIII comprising an amino acid sequence at least 90% identical to SEQ ID NO: 106.
63 . The method of claim 59 , wherein the cleavable linker is 20 to 50 amino acids long.
64 . The method of claim 63 , wherein the cleavable linker is about 30 amino acids long.
65 . A method of treating hemophilia A comprising intravenously administering a therapeutically effective amount of a chimeric protein to a subject in need thereof, wherein the chimeric protein comprises:
(i) a first polypeptide chain which comprises, from the N-terminus to the C-terminus thereof:
(a) a Factor VIII (“FVIII”) protein comprising the amino acid sequence of residues 1 to 745 of SEQ ID NO: 65, fused to a first XTEN sequence inserted immediately downstream of residue 745 of SEQ ID NO: 65, fused to residues 1649 to 2332 of SEQ ID NO: 65, and
(b) a first Fc region;
wherein the first XTEN sequence comprises the amino acid sequence of SEQ ID NO: 8; and
(ii) a second polypeptide chain which comprises, from the N-terminus to the C-terminus thereof:
(a) a von Willebrand Factor (“VWF”) protein comprising a D′ domain and a D3 domain of VWF, wherein the VWF protein comprises the amino acid sequence of residues 764 to 1240 of SEQ ID NO: 21 with alanine substitutions at residues 1099 and 1142 of SEQ ID NO: 21;
(b) a second XTEN sequence comprising the amino acid sequence of SEQ ID NO: 58;
(c) a cleavable linker comprising an a2 region of FVIII which comprises the amino acid sequence of Glu720 to Arg740 corresponding to SEQ ID NO: 65, wherein the a2 region is capable of being cleaved by thrombin; and
(d) a second Fc region, wherein the first Fc region is associated with the second Fc region through a disulfide bond, and wherein the chimeric protein is administered prophylactically.
66 . A method of treating hemophilia A comprising intravenously administering a therapeutically effective amount of a chimeric protein to a subject in need thereof, wherein the chimeric protein comprises:
(i) a first polypeptide chain which comprises from the N-terminus to the C-terminus thereof: a Factor VIII (“FVIII”) protein and a first Fc region;
wherein the FVIII protein comprises residues 1 to 745 and 1649 to 2332 of SEQ ID NO: 65with a first XTEN sequence inserted immediately downstream of residue 745; and
wherein the first XTEN sequence consists of at least about 288 amino acids and comprises an amino acid sequence of SEQ ID NO: 28, SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 31 or any combination thereof, and
(ii) a second polypeptide chain which comprises from the N-terminus to the C-terminus thereof:
a von Willebrand Factor (“VWF”) protein comprising a D′ domain and a D3 domain of VWF, a second XTEN sequence, a cleavable linker, and a second Fc region,
wherein the D′ domain and D3 domain comprises the amino acid sequence of residues 764 to 1240 of SEQ ID NO: 21 with alanine substitutions at the residues that correspond to positions 1099 and 1142 of SEQ ID NO: 21,
wherein the second XTEN sequence consists of at least about 144 amino acids and less than 288 amino acids and comprises an amino acid sequence of SEQ ID NO: 28, SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 31 or any combination thereof,
wherein the cleavable linker comprises an a2 region of FVIII which comprises the amino acid sequence of SEQ ID NO: 194, wherein the a2 region is capable of being cleaved by thrombin,
wherein the first Fc region is associated with the second Fc region through a disulfide bond.
67 . The method of claim 66 , wherein the cleavable linker is 30 to 35 amino acids long.
68 . The method of claim 66 , wherein the cleavable linker is about 30 amino acids long.
69 . The method of claim 66 , herein the first Fc region is associated with the second Fc region through two disulfide bonds.
70 . The method of claim 69 , wherein the first Fc region and the second Fc region are the same, and wherein the first Fc region and the second Fc region are derived from human IgG1.
71 . The method of claim 70 , wherein the VWF protein consists of the D′ domain and the D3 domain.
72 . The method of claim 66 , wherein the chimeric protein is administered prophylactically.
73 . The method of claim 65 , wherein the cleavable linker comprises the amino acid sequence of SEQ ID NO: 88.
74 . The method of claim 66 , wherein the cleavable linker comprises the amino acid sequence of SEQ ID NO: 88.
75 . The method of claim 1 , wherein the cleavable linker comprises the amino acid sequence of SEQ ID NO: 88.
76 . The method of claim 12 , wherein the cleavable linker comprises the amino acid sequence of SEQ ID NO: 88.
77 . The method of claim 66 , wherein the first XTEN sequence consists of about 288 amino acids.
78 . The method of claim 77 , wherein the first XTEN sequence comprises the amino acid sequence of SEQ ID NO: 8.
79 . The method of claim 66 , wherein the second XTEN consists of about 144 amino acids.
80 . The method of claim 79 , wherein the second XTEN comprises the amino acid sequence of SEQ ID NO: 58.
81 . A method of administering a chimeric protein to a subject who has hemophilia A, comprising intravenously administering about 0.1 to 400,000 μg/kg of the chimeric protein to the subject, wherein the chimeric protein comprises:
(i) a first polypeptide chain which comprises, from the N-terminus to the C-terminus thereof:
(a) a Factor VIII (“FVIII”) protein comprising a N-terminal portion and a C-terminal portion;
wherein the N-terminal portion of the FVIII protein comprises the A1domain, A2 domain, and a portion of the B domain of full length mature FVIII (SEQ ID NO: 65)
such that the N-terminal portion comprises the amino acid sequence of residues 1 to 745 of SEQ ID NO: 65;
wherein the N-terminal portion is fused to a first XTEN sequence inserted immediately downstream of amino acid 745 of SEQ ID NO: 65; and
wherein the C-terminal portion comprises the A3 domain, the C1 domain, and the C2 domain, such that the C-terminal portion comprises residues 1690-2332 of SEQ ID NO: 65;
(b) a first immunoglobulin (“Ig”) constant region or a portion thereof, wherein the first XTEN sequence comprises the amino acid sequence of SEQ ID NO: 8; and
(ii) a second polypeptide chain which comprises, from the N-terminus to the C-terminus thereof:
(a) a von Willebrand Factor (“VWF”) protein comprising a D′ domain and a D3 domain of VWF, wherein the VWF protein contains a residue other than cysteine substituted for residues corresponding to residues 1099 and 1142 of SEQ ID NO: 21;
(b) a second XTEN sequence comprising the amino acid sequence of SEQ ID NO: 58, wherein the second XTEN sequence contains less than 288 amino acid residues;
(c) a cleavable linker comprising an a2 region of FVIII which comprises the amino acid sequence of Glu720 to Arg740 corresponding to SEQ ID NO: 65, wherein the a2 region is capable of being cleaved by thrombin; and
(d) a second Ig constant region or a portion thereof, wherein the first polypeptide chain is associated with the second polypeptide chain through the first Ig constant region or a portion thereof and the second Ig constant region or a portion thereof.
82 . The method of claim 81 , wherein wherein the first Ig constant region or portion thereof is associated with the second Ig constant region or portion thereof through two disulfide bonds.
83 . The method of claim 82 , wherein wherein the first Ig constant region or portion thereof is a first Fc region and the second Ig constant region or portion thereof is a second Fc region.
84 . The method of claim 83 , wherein the cleavable linker is 20 to 50 amino acids long.
85 . The method of claim 84 , wherein the cleavable linker is about 30 amino acids long.
86 . The method of claim 81 , wherein the chimeric protein is administered prophylactically.
87 . The method of claim 81 , wherein the chimeric protein is administered for on-demand treatment.
88 . The method of claim 81 , wherein the chimeric protein is administered prior to, during, or after surgery.
89 . The method of claim 81 , wherein the chimeric protein is administered to control an acute bleeding episode.
90 . A method of administering a chimeric protein to a subject who has hemophilia A, comprising intravenously administering about 0.1 to 400,000 μg/kg of the chimeric protein to the subject, wherein the chimeric protein comprises:
(i) a first polypeptide chain which comprises, from the N-terminus to the C-terminus thereof:
(a) a Factor VIII (“FVIII”) protein comprising the amino acid sequence of residues 1 to 745 of SEQ ID NO: 65, fused to a first XTEN sequence inserted immediately downstream of residue 745 of SEQ ID NO: 65, fused to residues 1649 to 2332 of SEQ ID NO: 65, and
(b) a first Fc region;
wherein the first XTEN sequence comprises the amino acid sequence of SEQ ID NO: 8; and
(ii) a second polypeptide chain which comprises, from the N-terminus to the C-terminus thereof:
(a) a von Willebrand Factor (“VWF”) protein comprising a D′ domain and a D3 domain of VWF, wherein the VWF protein comprises the amino acid sequence of residues 764 to 1240 of SEQ ID NO: 21 with alanine substitutions at residues 1099 and 1142 of SEQ ID NO: 21,
(b) a second XTEN sequence comprising the amino acid sequence of SEQ ID NO: 58,
(c) a cleavable linker comprising the amino acid sequence of SEQ ID NO: 88, and
(d) a second Fc region;
wherein the first Fc region is associated with the second Fc region through a disulfide bond.
91 . A method of administering a chimeric protein to a subject who has hemophilia A, comprising intravenously administering about 0.1 to 400,000 μg/kg of the chimeric protein to the subject, wherein the chimeric protein comprises:
(i) a first polypeptide chain which comprises, from the N-terminus to the C-terminus thereof:
(a) a Factor VIII (“FVIII”) protein comprising an amino acid sequence that is at least 99% identical to SEQ ID NO: 67 with a first XTEN sequence inserted immediately downstream of the residue corresponding to residue 745 of SEQ ID NO: 67; and
(b) a first Fc region;
wherein the first XTEN sequence comprises the amino acid sequence of SEQ ID NO: 8; and
(ii) a second polypeptide chain which comprises, from the N-terminus to the C-terminus thereof:
(a) a von Willebrand Factor (“VWF”) protein comprising a D′ domain and a D3 domain of VWF, wherein the VWF protein contains a residue other than cysteine substituted for residues 1099 and 1142 of SEQ ID NO: 21;
(b) a second XTEN sequence comprising the amino acid sequence of SEQ ID NO: 58, wherein the second XTEN sequence contains less than 288 amino acid residues;
(c) a cleavable linker comprising an a2 region of FVIII which comprises the amino acid sequence of Glu720 to Arg740 corresponding to SEQ ID NO: 65, wherein the a2 region is capable of being cleaved by thrombin; and
(d) a second Fc region,
wherein the first Fc region is associated with the second Fc region through a disulfide bond.
92 . A method of administering a chimeric protein to a subject who has hemophilia A, comprising intravenously administering about 0.1 to 400,000 μg/kg of the chimeric protein to the subject, wherein the chimeric protein comprises:
(i) a first polypeptide chain which comprises a Factor VIII (“FVIII”) protein fused to a first immunoglobulin (“Ig”) constant region or a portion thereof,
wherein the FVIII protein comprises the amino acid sequence of residues 1 to 745 of SEQ ID NO: 202, fused to a first XTEN sequence inserted immediately downstream of residue 745 of SEQ ID NO: 202, fused to residues 746 to 1429 of SEQ ID NO: 202; and wherein the first XTEN sequence comprises the amino acid sequence of SEQ ID NO: 8; and
(ii) a second polypeptide chain which comprises a von Willebrand Factor (“VWF”) protein comprising a D′ domain and a D3 domain of VWF fused to a second Ig constant region or a portion thereof by a second XTEN sequence in-between,
wherein the VWF protein comprises the amino acid sequence of SEQ ID NO: 201;
wherein the second XTEN sequence comprises the amino acid sequence of SEQ ID NO: 58; and
wherein the second XTEN sequence is linked to the second Ig constant region or a
portion thereof by a linker comprising the amino acid sequence of SEQ ID NO: 88; wherein the first polypeptide chain is associated with the second polypeptide chain through the first Ig constant region or a portion thereof and the second Ig constant region or a portion thereof.
93 . The method of claim 81 , wherein the C-terminal portion of the FVIII protein comprises an amino acid sequence at least 95% identical to residues 1641 to 2332 of SEQ ID NO: 65.
94 . The method of claim 93 , wherein the VWF protein contains an alanine substitution at residue 1099 and residue 1142 of SEQ ID NO: 21.
95 . The method of claim 94 , wherein the first Fc region and the second Fc region are the same.
96 . The method of claim 95 , wherein the first Fc region and the second Fc region are derived from human IgG1.
97 . The method of claim 96 , wherein the VWF protein consists of the D′ domain and the D3 domain.
98 . The method of claim 81 , wherein the first Fc region is associated with the second Fc region through two disulfide bonds.
99 . The method of claim 81 , wherein the second XTEN sequence is fused to the linker such that the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 22.
100 . The method of claim 99 , wherein the first XTEN sequence is inserted into the FVIII protein such that the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 2.
101 . The method of claim 100 , wherein the first polypeptide chain comprises an amino acid sequence at least 99% identical to the amino acid sequence of SEQ ID NO: 173.
102 . The method of claim 101 , wherein the VWF protein consists of the D′ domain and the D3 domain.
103 . The method of claim 101 , wherein the VWF protein contains an alanine substitution at residue 1099 and residue 1142 of SEQ ID NO: 21.
104 . The method of claim 103 , wherein the first Fc region and the second Fc region are the same.
105 . The method of claim 104 , wherein the first Fc region and the second Fc region are derived from human IgG1.
106 . The method of claim 105 , wherein the VWF protein consists of the D′ domain and the D3 domain.
107 . The method of claim 104 , wherein the cleavable linker comprises an a2 region of FVIII comprising an amino acid sequence at least 90% identical to SEQ ID NO: 106.
108 . The method of claim 104 , wherein the cleavable linker is 20 to 50 amino acids long.
109 . The method of claim 108 , wherein the cleavable linker is about 30 amino acids long.
110 . The method of claim 92 , wherein the first Ig constant region or a portion thereof comprises a first Fc region and the second Ig constant region or a portion thereof comprises a second Fc region.
111 . The method of claim 92 , wherein the first Ig constant region or a portion thereof is associated with the second Ig constant region or a portion thereof by a covalent bond.
112 . The method of claim 92 , wherein the FVIII protein comprises a deletion of residues 746-1648 corresponding to native mature human FVIII protein (SEQ ID NO: 65).
113 . The method of claim 92 , wherein the first Ig constant region or a portion thereof is associated with the second Ig constant region or a portion thereof by a disulfide bond.
114 . The method of claim 92 , wherein the first polypeptide chain comprises an amino acid sequence at least 99% identical to SEQ ID NO: 173.
115 . The method of claim 92 , wherein the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 173.
116 . The method of claim 92 , wherein the second XTEN sequence is fused to the linker such that the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 22.
117 . The method of claim 92 , wherein the second XTEN sequence is linked to the second Ig constant region or a portion thereof by a linker consisting of the amino acid sequence of SEQ ID NO: 88.
118 . The method of claim 116 , wherein the first XTEN sequence is inserted into the FVIII protein such that the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 2.
119 . The method of claim 113 , wherein the first Fc region and the second Fc region are the same.
120 . The method of claim 113 , wherein the first Fc region and the second Fc region are derived from human IgG1.
121 . The method of claim 92 , wherein the first Ig constant region or a portion thereof is associated with the second Ig constant region or a portion thereof by two disulfide bonds.
122 . The method of claim 92 , wherein the VWF protein consists of the D′ domain and the D3 domain.
123 . A method of administering a chimeric protein to a subject who has hemophilia A, comprising intravenously administering about 0.1 to 400,000 μg/kg of the chimeric protein to the subject, wherein the chimeric protein comprises:
(i) a first polypeptide chain which comprises, from the N-terminus to the C-terminus thereof:
(a) a Factor VIII (“FVIII”) protein comprising the amino acid sequence of residues 1 to 745 of SEQ ID NO: 65, fused to a first XTEN sequence inserted immediately downstream of residue 745 of SEQ ID NO: 65, fused to residues 1649 to 2332 of SEQ ID NO: 65, and
(b) a first Fc region;
wherein the first XTEN sequence comprises the amino acid sequence of SEQ ID NO: 8; and
(ii) a second polypeptide chain which comprises, from the N-terminus to the C-terminus thereof:
(a) a von Willebrand Factor (“VWF”) protein comprising a D′ domain and a D3 domain of VWF, wherein the VWF protein comprises the amino acid sequence of residues 764 to 1240 of SEQ ID NO: 21 with alanine substitutions at residues 1099 and 1142 of SEQ ID NO: 21,
(b) a second XTEN sequence comprising the amino acid sequence of SEQ ID NO: 58, wherein the second XTEN sequence contains less than 288 amino acid residues;
(c) a cleavable linker comprising an a2 region of FVIII which comprises the amino acid sequence of Glu720 to Arg740 corresponding to SEQ ID NO: 65, wherein the a2 region is capable of being cleaved by thrombin; and
(d) a second Fc region;
wherein the first Fc region is associated with the second Fc region through a disulfide bond.
124 . The method of claim 123 , wherein the first Fc region and the second Fc region are the same.
125 . The method of claim 124 , wherein the first Fc region and the second Fc region are derived from human IgG1.
126 . The method of claim 125 , wherein the VWF protein consists of the D′ domain and the D3 domain.
127 . The method of claim 124 , wherein the cleavable linker comprises an a2 region of FVIII comprising an amino acid sequence at least 90% identical to SEQ ID NO: 106.
128 . The method of claim 124 , wherein the cleavable linker is 20 to 50 amino acids long.
129 . The method of claim 128 , wherein the cleavable linker is about 30 amino acids long.
130 . A method of administering a chimeric protein to a subject who has hemophilia A, comprising intravenously administering about 0.1 to 400,000 μg/kg of the chimeric protein to the subject, wherein the chimeric protein comprises:
(i) a first polypeptide chain which comprises, from the N-terminus to the C-terminus thereof:
(a) a Factor VIII (“FVIII”) protein comprising the amino acid sequence of residues 1 to 745 of SEQ ID NO: 65, fused to a first XTEN sequence inserted immediately downstream of residue 745 of SEQ ID NO: 65, fused to residues 1649 to 2332 of SEQ ID NO: 65, and
(b) a first Fc region;
wherein the first XTEN sequence comprises the amino acid sequence of SEQ ID NO: 8; and
(ii) a second polypeptide chain which comprises, from the N-terminus to the C-terminus thereof:
(a) a von Willebrand Factor (“VWF”) protein comprising a D′ domain and a D3 domain of VWF, wherein the VWF protein comprises the amino acid sequence of residues 764 to 1240 of SEQ ID NO: 21 with alanine substitutions at residues 1099 and 1142 of SEQ ID NO: 21;
(b) a second XTEN sequence comprising the amino acid sequence of SEQ ID NO: 58;
(c) a cleavable linker comprising an a2 region of FVIII which comprises the amino acid sequence of Glu720 to Arg740 corresponding to SEQ ID NO: 65, wherein the a2 region is capable of being cleaved by thrombin; and
(d) a second Fc region,
wherein the first Fc region is associated with the second Fc region through a disulfide bond, and
wherein the chimeric protein is administered prophylactically.
131 . A method of administering a chimeric protein to a subject who has hemophilia A, comprising intravenously administering about 0.1 to 400,000 μg/kg of the chimeric protein to the subject, wherein the chimeric protein comprises:
(i) a first polypeptide chain which comprises from the N-terminus to the C-terminus thereof: a Factor VIII (“FVIII”) protein and a first Fc region;
wherein the FVIII protein comprises residues 1 to 745 and 1649 to 2332 of SEQ ID NO: 65 with a first XTEN sequence inserted immediately downstream of residue 745; and
wherein the first XTEN sequence consists of at least about 288 amino acids and comprises an amino acid sequence of SEQ ID NO: 28, SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 31 or any combination thereof,
and
(ii) a second polypeptide chain which comprises from the N-terminus to the C-terminus thereof: a von Willebrand Factor (“VWF”) protein comprising a D′ domain and a D3 domain of VWF, a second XTEN sequence, a cleavable linker, and a second Fc region,
wherein the D′ domain and D3 domain comprises the amino acid sequence of residues 764 to 1240 of SEQ ID NO: 21 with alanine substitutions at the residues that correspond to positions 1099 and 1142 of SEQ ID NO: 21,
wherein the second XTEN sequence consists of at least about 144 amino acids and less than 288 amino acids and comprises an amino acid sequence of SEQ ID NO: 28, SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 31 or any combination thereof,
wherein the cleavable linker comprises an a2 region of FVIII which comprises the amino acid sequence of SEQ ID NO: 194, wherein the a2 region is capable of being cleaved by thrombin,
wherein the first Fc region is associated with the second Fc region through a disulfide bond.
132 . The method of claim 131 , wherein the cleavable linker is 30 to 35 amino acids long.
133 . The method of claim 131 , wherein the cleavable linker is about 30 amino acids long.
134 . The method of claim 131 , herein the first Fc region is associated with the second Fc region through two disulfide bonds.
135 . The method of claim 134 , wherein the first Fc region and the second Fc region are the same, and wherein the first Fc region and the second Fc region are derived from human IgG1.
136 . The method of claim 135 , wherein the VWF protein consists of the D′ domain and the D3 domain.
137 . The method of claim 131 , wherein the chimeric protein is administered prophylactically.
138 . The method of claim 130 , wherein the cleavable linker comprises the amino acid sequence of SEQ ID NO: 88.
139 . The method of claim 131 , wherein the cleavable linker comprises the amino acid sequence of SEQ ID NO: 88.
140 . The method of claim 81 , wherein the cleavable linker comprises the amino acid sequence of SEQ ID NO: 88.
141 . The method of claim 91 , wherein the cleavable linker comprises the amino acid sequence of SEQ ID NO: 88.
142 . The method of claim 131 , wherein the first XTEN sequence consists of about 288 amino acids.
143 . The method of claim 142 , wherein the first XTEN sequence comprises the amino acid sequence of SEQ ID NO: 8.
144 . The method of claim 131 , wherein the second XTEN consists of about 144 amino acids.
145 . The method of claim 144 , wherein the second XTEN comprises the amino acid sequence of SEQ ID NO: 58.
146 . The method of claim 81 , comprising administering about 0.1 to 100,000 μg/kg of the chimeric protein to the subject.
147 . The method of claim 81 , comprising administering about 1,000 to 400,000 μg/kg of the chimeric protein to the subject.
148 . The method of claim 90 , comprising administering about 0.1 to 100,000 μg/kg of the chimeric protein to the subject.
149 . The method of claim 90 , comprising administering about 1,000 to 400,000 μg/kg of the chimeric protein to the subject.
150 . The method of claim 91 , comprising administering about 0.1 to 100,000 μg/kg of the chimeric protein to the subject.
151 . The method of claim 91 , comprising administering about 1,000 to 400,000 μg/kg of the chimeric protein to the subject.
152 . The method of claim 92 , comprising administering about 0.1 to 100,000 μg/kg of the chimeric protein to the subject.
153 . The method of claim 92 , comprising administering about 1,000 to 400,000 μg/kg of the chimeric protein to the subject.
154 . The method of claim 123 , comprising administering about 0.1 to 100,000 μg/kg of the chimeric protein to the subject.
155 . The method of claim 123 , comprising administering about 1,000 to 400,000 μg/kg of the chimeric protein to the subject.
156 . The method of claim 130 , comprising administering about 0.1 to 100,000 μg/kg of the chimeric protein to the subject.
157 . The method of claim 130 , comprising administering about 1,000 to 400,000 μg/kg of the chimeric protein to the subject.
158 . The method of claim 131 , comprising administering about 0.1 to 100,000 μg/kg of the chimeric protein to the subject.
159 . The method of claim 131 , comprising administering about 1,000 to 400,000 μg/kg of the chimeric protein to the subject.
160 . The method of claim 1 , wherein the VWF protein contains an alanine substitution at residue 1099 and residue 1142 of SEQ ID NO: 21.
161 . The method of claim 81 , wherein the VWF protein contains an alanine substitution at residue 1099 and residue 1142 of SEQ ID NO: 21.